{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Al Jurdi A"],"funding":["Massachusetts General Hospital"],"pubmed_abstract":["<h4>Introduction</h4>Studies have shown reduced antiviral responses in kidney transplant recipients (KTRs) following SARS-CoV-2 mRNA vaccination, but data on post-vaccination alloimmune responses and antiviral responses against the Delta (B.1.617.2) variant are limited.<h4>Materials and methods</h4>To address this issue, we conducted a prospective, multi-center study of 58 adult KTRs receiving mRNA-BNT162b2 or mRNA-1273 vaccines. We used multiple complementary non-invasive biomarkers for rejection monitoring including serum creatinine, proteinuria, donor-derived cell-free DNA, peripheral blood gene expression profile (PBGEP), urinary <i>CXCL9</i> mRNA and <i>de novo</i> donor-specific antibodies (DSA). Secondary outcomes included development of anti-viral immune responses against the wild-"],"journal":["Frontiers in immunology"],"pagination":["838985"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8913529"],"repository":["biostudies-literature"],"pubmed_title":["Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination."],"pmcid":["PMC8913529"],"pubmed_authors":["Alghamdi A","Bohan B","Solhjou Z","Pattanayak V","Mohammed MT","Kotton CN","Al Jurdi A","Azzi JR","Hullekes FE","Efe O","Patel P","Riella LV","Borges TJ","Cravedi P","Gassen RB","Choi JY","Lape IT","Rosales I"],"additional_accession":[]},"is_claimable":false,"name":"Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.","description":"<h4>Introduction</h4>Studies have shown reduced antiviral responses in kidney transplant recipients (KTRs) following SARS-CoV-2 mRNA vaccination, but data on post-vaccination alloimmune responses and antiviral responses against the Delta (B.1.617.2) variant are limited.<h4>Materials and methods</h4>To address this issue, we conducted a prospective, multi-center study of 58 adult KTRs receiving mRNA-BNT162b2 or mRNA-1273 vaccines. We used multiple complementary non-invasive biomarkers for rejection monitoring including serum creatinine, proteinuria, donor-derived cell-free DNA, peripheral blood gene expression profile (PBGEP), urinary <i>CXCL9</i> mRNA and <i>de novo</i> donor-specific antibodies (DSA). Secondary outcomes included development of anti-viral immune responses against the wild-","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T08:53:46.53Z","creation":"2025-04-04T08:53:46.53Z"},"accession":"S-EPMC8913529","cross_references":{"pubmed":["35281011"],"doi":["10.3389/fimmu.2022.838985"]}}